» Articles » PMID: 16481903

Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla

Overview
Journal Invest Radiol
Specialty Radiology
Date 2006 Feb 17
PMID 16481903
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We sought to determine the relaxivity and accurate relaxation rates of Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA at 0.2, 1.5, and 3 T in human blood plasma.

Materials And Methods: Contrast media concentrations between 0.01 and 16 mM in human plasma were used for relaxation measurements. The R1 and R2 relaxation rates and r1 and r2 relaxivities were determined.

Results: Gd-BOPTA produced the highest relaxation rates and relaxivities at all field strengths. The r1 and r2 values for Gd-BOPTA were 107-131% and 91-244% higher than for Gd-DTPA, respectively, and 72-98% and 82-166% higher than for Gd-BT-DO3A. Higher field strengths resulted in lower values of R1, R2, and r1 for all contrast agents tested and of r2 for Gd-DTPA and Gd-BT-DO3A. A linear dependence of R1 and R2 on concentration was found for Gd-DTPA and Gd-BT-DO3A and a nonlinear dependence for Gd-BOPTA for concentrations larger than 1 mM. The r1 and r2 relaxivity of Gd-BOPTA increased with decreasing concentration.

Conclusions: Gd-BOPTA demonstrates the highest longitudinal r1 at all field strengths, which is ascribable to weak protein interaction. The R2/R1 ratio increases at higher field strength only for Gd-BOPTA, hence very short echo times are required for Gd-BOPTA to benefit from the higher longitudinal relaxivity.

Citing Articles

Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.

Titova S, Kruglova M, Stupin V, Manturova N, Silina E Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005968 PMC: 11858778. DOI: 10.3390/ph18020154.


MRI contrast agents and retention in the brain: review of contemporary knowledge and recommendations to the future.

Vymazal J, Rulseh A Insights Imaging. 2024; 15(1):179.

PMID: 39060665 PMC: 11282029. DOI: 10.1186/s13244-024-01763-z.


Contrast Agents Based on Human Serum Albumin and Nitroxides for H-MRI and Overhauser-Enhanced MRI.

Mitin D, Bullinger F, Dobrynin S, Engelmann J, Scheffler K, Kolokolov M Int J Mol Sci. 2024; 25(7).

PMID: 38612851 PMC: 11012161. DOI: 10.3390/ijms25074041.


Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery.

Lopuszynska N, Weglarz W Nanomaterials (Basel). 2023; 13(15).

PMID: 37570481 PMC: 10420849. DOI: 10.3390/nano13152163.


Engineered Protein-Iron Oxide Hybrid Biomaterial for MRI-traceable Drug Encapsulation.

Hill L, Britton D, Jihad T, Punia K, Xie X, Delgado-Fukushima E Mol Syst Des Eng. 2023; 7(8):915-932.

PMID: 37274761 PMC: 10237276. DOI: 10.1039/d2me00002d.